YesWeHack Raises 26 Million Euros to Accelerate Its Growth and International Expansion
YesWeHack, the global Bug Bounty and vulnerability management platform, announces a €26 million Series C funding round.
In a world where cyber risks are more strategic and complex than ever, YesWeHack will use this funding to invest in Artificial Intelligence, launch new innovative solutions and expand its international growth.
The round is led by Wendel, alongside new investors such as Adelie and Seventure Partners, as well as reinvestment from Bpifrance, Open CNP* and Eiffel Investment Group. YesWeHack is also delighted to welcome Renaud Deraison, Co-Founder of Tenable and Senior Advisor to Wendel Growth, to its Board of Directors.
YesWeHack is the leading security testing solution for organisations of all sizes. Its Bug Bounty platform mobilises a community of tens of thousands ethical hackers to test the security of its customers in an agile and cost-effective way, thus reducing their attack surface.
With more than 500 customers across 40 countries, YesWeHack covers all business sectors, including:
- 70% of “CAC 40” ** companies
- Global organisations such as Louis Vuitton, Decathlon and Tencent
- Telecoms companies such as Orange, Ooredoo and Telenor
- Unicorns such as Contentsquare, Doctolib and Blablacar
- Public institutions in countries such as France, Spain, Canada and Singapore
Since its last funding round in 2021, YesWeHack has increased by six times its annual recurring revenue and tripled the number of ethical hackers registered on its platform. The company has also developed integrated pentest and attack surface management solutions, offering customers a unified approach to monitoring their online risks and vulnerabilities.
Guillaume Vassault-Houlière, CEO and Co-Founder of YesWeHack, commented: “This funding round is a vote of confidence in our commitment to excellence and our ambitious vision. Thanks to this investment, YesWeHack will deliver even higher levels of customer satisfaction and continue developing innovative solutions in one of the most dynamic segments of cybersecurity. We would like to thank our investors, both longstanding and new, and are honoured by their trust.”
Antoine Izsak, Head of Growth Equity at Wendel, said: “Bug bounty is now recognised as a must by some of the companies most exposed to the cyber threat. We are delighted to be working with the European leader YesWeHack, which stands out for its quality of service, compliance with regulations and the relevance of its technological roadmap for customers who are increasingly overwhelmed by the growing volume of vulnerabilities."
Renaud Deraison, Co-Founder of Tenable, Senior Advisor to Wendel Growth and new member of the Board of Directors added:"YesWeHack's community of experts is one of the most qualified in the world to continuously test the security of its customers' digital infrastructure. I'm honoured to join YesWeHack's Board of Directors and look forward to contributing to the company's mission alongside Guillaume and his team."
*The Corporate Venture Capital fund of CNP Assurances.
**The CAC 40 is Paris’ main stock market index.
About YesWeHack
YesWeHack is a leading Bug Bounty and Vulnerability Management Platform. Founded by ethical hackers in 2015, YesWeHack connects organisations worldwide to tens of thousands of ethical hackers, who uncover vulnerabilities in websites, mobile apps, connected devices and digital infrastructure.
Our Bug Bounty Programs benefit from in-house triage, personalised support, a customisable model and results-based pricing. Clients include Tencent, Swiss Post, Telenor, Ooredoo, Orange, the French Ministry of Armed Forces and several other governments worldwide.
The YesWeHack platform offers a range of integrated, API-based solutions: Bug Bounty (crowdsourcing vulnerability discovery), Vulnerability Disclosure Policy (creating and managing a secure channel for external vulnerability reporting), Pentest Management (managing pentest reports from all sources) and Attack Surface Management (continuously mapping online exposure and detecting attack vectors).
For more information, visit: www.yeswehack.com
This transaction was carried out with the expert support of Trachet Ltd.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240610793319/en/
Contact information
Press
press@yeswehack.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom